Fibrin fuels thromboinflammation and brain damage in COVID-19

Researchers reveal fibrin’s critical role in COVID-19 by driving thromboinflammation and neuropathology, and highlight a potential antibody therapy to mitigate these effects.

Google’s Verily to offer GLP-1 drugs through Lightpath, its retooled chronic care app

For the second time in as many years, Google’s health tech spinout Verily is pivoting. The company announced Tuesday that it will phase out its

June 11, 2024

Webinar on Early Detection of Colorectal Cancer – Exploring New Laboratory Diagnostic Options – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous 18.03.2024 / 13:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed:

March 19, 2024

The green tea effect: From gut microbes to weight loss, new insights emerge

The impact of green tea and its functional components on body weight and gut microbiota regulation.

August 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.